Viralgen

Executive Summary

Viralgen is a leading contract development and manufacturing organization (CDMO) exclusively focused on adeno-associated virus (AAV) vector production for gene therapies. Founded in 2017 and headquartered in San Sebastián, Spain, the company operates as an independent subsidiary of AskBio. It provides end-to-end cGMP manufacturing services, from early-stage development to commercial-scale production, leveraging its proprietary Aava™ platform. With dedicated large-scale facilities, Viralgen positions itself as a world leader in AAV manufacturing, serving a growing pipeline of gene therapy clients. The company's expertise and infrastructure are critical as the gene therapy field advances toward commercialization, making Viralgen a key partner for developers seeking reliable, high-quality AAV supply. As the gene therapy market expands, Viralgen benefits from increasing demand for specialized CDMO services. Its strategic relationship with AskBio provides a stable client base and access to innovative technologies. However, the competitive landscape includes other CDMOs investing in viral vector capacity. Viralgen's success hinges on its ability to maintain high yields, scale efficiently, and secure new contracts. With a focus on quality and proprietary platform advantages, Viralgen is well-positioned to capture a significant share of the AAV manufacturing market, though execution risks and competitive dynamics remain.

Upcoming Catalysts (preview)

• Q1 2027Commercial launch of a client's AAV gene therapy manufactured by Viralgen60% success
• Q4 2026Announcement of a new long-term manufacturing agreement with a major pharmaceutical company50% success
• Q3 2026Completion and qualification of expanded manufacturing capacity at San Sebastián facility80% success